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eIF2α signaling regulates ischemic 
osteonecrosis through endoplasmic 
reticulum stress
Daquan Liu1,2,3, Yunlong Zhang1,4, Xinle Li1,3,5, Jie Li1, Shuang Yang1, Xiaoxue Xing6, Guanwei 
Fan6, Hiroki Yokota7 & Ping Zhang1,3,5,7
Osteonecrosis of the femoral head (ONFH) primarily results from ischemia/hypoxia to the femoral head, 
and one of the cellular manifestations is the endoplasmic reticulum (ER) stress. To understand possible 
linkage of ischemic osteonecrosis to the ER stress, a surgery-induced animal model was employed and 
salubrinal was administered to evaluate the role of ER stress. Salubrinal is a synthetic chemical that 
inhibits de-phosphorylation of eIF2α, and it can suppress cell death from the ER stress at a proper 
dose. The results indicated that the ER stress was associated with ONFH and salubrinal significantly 
improved ONFH-induced symptoms such as osteonecrosis, bone loss, reduction in vessel perfusion, and 
excessive osteoclastogenesis in the femoral head. Salubrinal also protected osteoblast development 
by upregulating the levels of ATF4, ALP and RUNX2, and it stimulated angiogenesis of endothelial cells 
through elevating ATF4 and VEGF. Collectively, the results support the notion that the ER stress is an 
important pathological outcome in the surgery-induced ONFH model, and salubrinal improves ONFH 
symptoms by enhancing angiogenesis and bone healing via suppressing the ER stress.
The endoplasmic reticulum (ER) is a cellular organelle for modifying, folding, and transporting various proteins1. 
When ER homeostasis is disturbed, for example by ischemia/hypoxia, the unfolded protein response (UPR) takes 
place followed by induction of the stress to the ER1, 2. When cells experience the prolonged and unmitigated ER 
stress, they undergo apoptosis1, 3. Although the ER stress has been reported to be linked to various diseases such 
as diabetes4, neurodegenerative diseases5, osteoporosis6, and osteogenesis imperfecta7, the role of the ER stress in 
the pathogenesis of ischemic bone diseases remains unclear.
Ischemia/hypoxia is known to induce the ER stress8 and increases mortality, for instance, in the mouse model 
of acute myocardial infarction9. However, little is known about whether ischemic osteonecrosis of the femoral 
head (ONFH) triggers the ER stress, and whether any pharmacological approach for suppressing the ER stress 
may mitigate symptoms. ONFH, a serious orthopedic problem in the hip joint, results from an impaired blood 
supply to the femoral head10, 11. Its etiologic risk factors include trauma12, 13, excessive alcohol intake14, corticoster-
oid use15–17, and Legg-Calve-Perthes disease18, 19. A lack of proper blood circulation results in necrosis, followed 
by a collapse of the femoral head20. In the United States, approximately 50,000 hip replacements are annually 
performed for patients with ONFH21. Surgical therapies, including autologous bone marrow transplantation, 
core decompression osteotomies, vascularized or non-vascularised bone grafting, and total hip replacement, are 
primary treatments for the end-stage ONFH22. Non-surgical therapies include drugs for anticoagulation and 
anti-osteoporosis, a reduction in weight bearing, hyperbaric oxygen therapy, and electromagnetic and shockwave 
stimulation23, 24. Because of limited efficacy and potential side effects, however, few non-surgical therapies are 
satisfactory. In this study, we examined whether the ER stress is triggered in the ischemic ONFH, and evaluated 
whether alleviating the ER stress may provide a novel pharmacological approach in the treatment for ONFH.
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Eukaryotic translation initiation factor 2 subunit alpha (eIF2α)25, 26 is an important member of protein syn-
thesizing machinery in the regulatory axis in the ER stress that involves protein kinase RNA-like ER kinase 
(PERK) and activating transcription factor 4 (ATF4). Following the accumulation of misfolded proteins, PERK 
is activated after dissociation of glucose-regulated protein 78 (GRP78) and attenuates protein synthesis by phos-
phorylating eIF2α. ATF4 induces anti-stress responses by promoting transcription of specific genes such as ER 
chaperones (such as GRP78) and leading to, for instance, autophagy. Besides the PERK/ATF4 axis, other regula-
tors include growth arrest and DNA damage inducible protein (GADD34) and CCAAT/enhancer binding protein 
homologous protein (CHOP). Activation of GADD34 regulates a recover process from the inhibition of protein 
synthesis. In response to the prolonged and unmitigated ER stress, CHOP may induce apoptosis by stimulating 
pro-apoptotic factors (e.g., death receptor 5, DR5) and blocking anti-apoptotic B cell CLL/lymphoma 2 (BCL-2)26.
Salubrinal (480 Da, C21H17Cl3N4OS) is a selective inhibitor of protein phosphatase I (PP1) complex, which 
de-phosphorylates eIF2α25, 26. Salubrinal is known to regulate bone metabolism by elevating phosphorylated 
eIF2α (p-eIF2α) and activating transcription factors such as ATF427. It is reported that salubrinal stimulates bone 
healing, and serves as a potential drug candidate for treatment of osteoarthritis and osteoporosis by reducing joint 
inflammation and bone loss27–29. We have recently demonstrated that the ER stress plays a key role in the patho-
genesis of disuse osteoporosis, and salubrinal attenuates unloading-induced bone loss by altering the proliferation 
and differentiation of osteoblasts and osteoclasts30. In the present study, we investigated whether the ER stress is 
triggered in the ischemic ONFH, and whether salubrinal is effective in the treatment of ONFH. We employed a 
rat model of surgically induced ONFH, and evaluated angiogenesis and bone remodelling by examining fates of 
endothelial cells, osteoclasts, and osteoblasts.
Results
Salubrinal has no significant effects on bone metabolism of normal animals. The body weight of 
animals in the sham control and salubrinal-treated sham control groups were not significant difference (P > 0.05, 
Supplemental Fig. 1a). For pDEXA scanning, BMD and BMC of the femurs in these two groups were not signif-
icant difference (P > 0.05, Supplemental Fig. 1a,b). The images of H&E staining indicated that the general struc-
ture and B.Ar/T.Ar of the femoral heads were not significant difference in these groups (P > 0.05, Supplemental 
Fig. 1d,e). The result indicated that salubrinal had no significant effects on bone metabolism of normal animals. 
We thus did not include salubrinal-treated sham control groups in the subsequent experiments.
Salubrinal suppresses bone loss in ONFH. In the sham control group, the femoral head and neck surface 
was not detectably altered. However, the femoral head surface in the ON group exhibited “moth eaten” appear-
ance and the femoral neck was thinned. Compared to the ON group, the salubrinal-treated group suppressed 
osteonecrosis-driven bone loss in the head and neck (Fig. 1a). In the ON group, the values of BV/TV, Tb.N, Tb.Th, 
and BMD/BMC were decreased, and the value of Tb.Sp was increased (all P < 0.01). Salubrinal significantly 
increased the values of BV/TV, Tb.N, and Tb.Th, as well as the change of femoral BMD/BMC. It also decreased 
the value of Tb.Sp (all P < 0.05; Fig. 1b–g). Regarding the results of H&E staining in the femoral head (Fig. 1h,j), 
the ON group exhibited the lowest B.Ar/T.Ar with the highest percentage of empty lacunae (both P < 0.001). The 
salubrinal-treated group significantly improved those values (both P < 0.001; Fig. 1i,k).
Salubrinal inhibits osteoclastogenesis in ONFH. To investigate whether salubrinal affected the bone 
resorption of osteoclasts in ONFH in vivo, we conducted TRAP staining (Fig. 2a). The osteoclast surface (%) 
was increased in the ON group (P < 0.01), while this increase was suppressed in the salubrinal-treated group 
(P < 0.05; Fig. 2b). Regarding TRAP-positive multinuclear cells (more than 3 nuclei) identified as matured oste-
oclasts in osteoclast formation in vitro assay (Fig. 2c), the ON group significantly increased the osteoclast area 
(Fig. 2d) and the osteoclast number (Fig. 2e) (both P < 0.001), but the salubrinal-treated group significantly sup-
pressed their increases (both P < 0.001). To determine whether salubrinal affected the proliferation and popula-
tion of osteoclast progenitors, we counted CFU-M/CFU-GM. The numbers of CFU-M/CFU-GM were increased 
in the ON group (both P < 0.01), while salubrinal significantly reduced them (both P < 0.01; Fig. 2f,g).
To evaluate whether salubrinal affected the function of osteoclast lineage in ONFH, we performed migration, 
adhesion, and pit formation assays. In the ON group, migration (Fig. 2h) and adhesion (Fig. 2i) of pre-osteoclasts 
were stimulated, and an increased capacity for bone resorption was observed in the pit formation assay (all 
P < 0.01; Fig. 2j). Those activities were significantly reduced in the salubrinal-treated group (all P < 0.01; 
Fig. 2k–m).
Salubrinal promotes osteoblast differentiation in ONFH. To evaluate the differentiation of osteo-
blasts and fibroblasts from mesenchymal stem cells, osteoblasts were identified using MacNeal’s staining in vivo 
(Fig. 3a) or ALP staining in vitro (Fig. 3b), and fibroblasts were stained using a HEMA-3 quick staining kit. The 
number of osteoblasts (Fig. 3a,b) and the number of CFU-F (Fig. 3c) were not significantly different in the sham 
control and ON groups (all P > 0.05). However, the numbers were significantly increased in the salubrinal-treated 
group (all P < 0.01; Fig. 3d–f).
Salubrinal promotes osteogenesis by increasing p-eIF2α in vitro. To evaluate whether salubrinal 
improved osteogenesis against the ER stress, cell viability and the expression of osteoblast markers were deter-
mined. Tunicamycin was used to activate ER stress signaling, and Calyculin A (CA, a specific inhibitor of PP1) 
was employed as a positive control to salubrinal25. We first evaluated the effects of tunicamycin, salubrinal, and 
CA to MC3T3-E1 cells. The result indicated that the non-toxic dose of salubrinal was 0.2 to 5 μM, while that for 
CA was 0.05 to 0.2 nM. We thereafter employed those concentrations, and evaluated their effects in the presence 
of tunicamycin. Tunicamycin inhibited viability of MC3T3-E1cells in a dose-dependent manner at 0.05, 0.1, 0.25, 
0.5, 1, and 2.5 μg/ml. Interestingly, administration of 5 μM salubrinal or 0.2 nM CA partially restored cell viability 
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in the presence of 100 ng/ml tunicamycin (both P < 0.001; Fig. 3g). However, salubrinal or CA was unable to 
rescue MC3T3-E1 cells at higher concentrations of tunicamycin (above 250 ng/ml, all P > 0.05; Supplemental 
Fig. 2a).
To investigate the role of eIF2α in the effect of salubrinal on osteogenesis, the cell viability and the expression 
of osteoblast markers were determined in MC3T3-E1 cells using eIF2α RNA interference. Transfection with 
eIF2α siRNA blocked the effect of salubrinal on cells viability under ER stress (P < 0.01; Fig. 3h). Furthermore, 
the protein levels of p-eIF2α, ATF4, ALP and RUNX2 in MC3T3-E1 cells were examined at 48 h after admin-
istration of 100 ng/ml tunicamycin with 5 μM salubrinal (Fig. 3i). Tunicamycin significantly inhibited the levels 
of ALP and RUNX2, while salubrinal increased the levels of p-eIF2α, ATF4, ALP, and RUNX2 (all P < 0.01). 
Figure 1. Salubrinal suppresses bone loss in ONFH. (a) Representative μ-CT reconstructed image of the 
femoral head (Bar = 1 mm). (b–e) Architectural properties in ONFH were measured by μ-CT. (b) Fractional 
bone volume (BV/TV). (c) Trabecular number (Tb.N). (d) Trabecular thickness (Tb.Th). (e) Trabecular spacing 
(Tb.Sp). (f) Bone mineral density (BMD). (g) Bone mineral content (BMC). (h–j) Representative histological 
images of the femoral head by H&E staining (h) 100×, Bar = 200 μm, and (j) 400×, Bar = 50 μm. Empty lacunae 
were indicated by the arrows. (i) Ratio of the trabecular bone area to the tissue area (B.Ar/T.Ar). (k) Percentage 
of empty lacunae. The asterisks (*, **, and ***) represent P < 0.05, P < 0.01, and P < 0.001, respectively (n = 12) 
(Sham: sham control group, ON: osteonecrosis group, ON + S: salubrinal treated osteonecrosis group).
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Compared to scrambled siRNA, eIF2α siRNA blocked the effect of salubrinal on the expression of p-eIF2α, ATF4, 
ALP, and RUNX2 under ER stress (all P < 0.05; Fig. 3j–m).
Salubrinal elevates vessel density in ONFH. To investigate whether salubrinal improves blood per-
fusion in the ischemic femoral head, we determined the vessels in the femoral head using ink perfusion 
Figure 2. Salubrinal inhibits osteoclastogenesis in ONFH. (a) Representative histological images of the femoral 
head by TRAP staining. TRAP-positive cells, in red color, indicated by the arrows (400×, Bar = 50 μm). (b) 
Osteoclast surface (%). (c) Representative images of mature osteoclasts formation in vitro by TRAP staining 
(200×, Bar = 100 μm). (d) Percentage of the matured osteoclasts area. (e) Matured osteoclasts number. (f) 
CFU-M. (g) CFU-GM. (h) Representative images of pre-osteoclasts migration by crystal violet staining (200×, 
Bar = 100 μm). (i) Number of migratory pre-osteoclasts. (j) Representative images of pre-osteoclasts adhesion 
with crystal violet staining (200×, Bar = 100 μm). (k) Numbers of adherent pre-osteoclasts. (l) Representative 
images of bone resorption capacity of osteoclasts with crystal violet staining (400×, Bar = 50 μm). (m) 
Percentages of the pit area to total area in each field view from three groups. The asterisks (*, **, and ***) 
represent P < 0.05, P < 0.01, and P < 0.001, respectively (n = 12).
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angiography (Fig. 4a). The ON group decreased the vessel numbers and vessel area (both P < 0.001), while the 
salubrinal-treated group improved them (both P < 0.001; Fig. 4b,c).
Salubrinal protects endothelial cells by elevating p-eIF2α in vitro. In response to salubrinal, cell 
viability of human umbilical vein endothelial cells (HUVECs) was lowered at the concentration above 10 μM (all 
P < 0.05), but no detectable change in cell viability was observed at 0.2 to 5 μM (Fig. 4d). Thus, we employed 0.2 
Figure 3. Salubrinal promotes osteoblast differentiation in ONFH. (a) Representative histological images of the 
femoral head by MacNeal’s staining. Osteoblasts, located on trabecular surface, were indicated by the arrows. 
(400×, Bar = 50 μm). (b) Quantification of the osteoblast number normalized to the total trabecular surface. (c) 
Representative images of osteoblast differentiation in vitro by ALP staining (400×, Bar = 50 μm). (d) ALP+ cells 
(%). (e) Colonies of fibroblasts stained using a HEMA-3 quick staining kit. (f) Numbers of colonies with more 
than 50 cells (the colonies were indicated by the circles). (g,h) Statistical analysis for cell viability of MC3T3-E1 
cells. (i) Representative images of Western blotting for salubrinal’s protection of osteogenesis against the ER 
stress. The levels of p-eIF2α (j), ATF4 (k), ALP (l), and RUNX2 (m) are shown. The experiment was conducted 
in triplicate. The asterisks (*, ** and ***) represent P < 0.05, P < 0.01, and P < 0.001, respectively, and “ns” 
represents P > 0.05 (Tm: Tunicamycin, S: Salubrinal, and CA: Calyculin A).
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to 5 μM salubrinal to HUVECs and evaluated salubrinal’s effect in the presence of an ER stress inducer, tunica-
mycin. Tunicamycin inhibited cell viability of HUVECs in a dose-dependent manner (from 250 ng/ml to 5 μg/
ml, all P < 0.05; Fig. 4e). Administration of 5 μM salubrinal restored cell viability in the presence of 500 ng/ml 
tunicamycin (P < 0.05; Fig. 4f). However, 5 μM salubrinal was unable to rescue the viability of HUVECs that were 
treated with higher concentrations of tunicamycin (more than 1 μg/ml, all P > 0.05, Supplemental Fig. 3a–c). 
The results indicated that 500 ng/ml tunicamycin induces significant responses in HUVECs. The dose of 500 ng/
ml tunicamycin was thus used to induce ER stress in HUVECs. Furthermore, compared to scrambled siRNA, 
eIF2α siRNA transfection blocked the effect of salubrinal for restoring cell viability of HUVECs in the presence 
of 500 ng/ml tunicamycin (all P < 0.05; Fig. 4g).
To investigate whether salubrinal affected migration and angiogenesis of HUVECs in the presence of tunica-
mycin, we performed assays for migration, wound healing and tube formation in vitro. In the migration (Fig. 5a) 
and wound healing (Fig. 5b) assays, tunicamycin inhibited the migration and wound recovery of HUVECs (both 
P < 0.05). Salubrinal rescued migration and wound recovery of HUVECs in the presence of tunicamycin (both 
P < 0.05). However, compared to scrambled siRNA, eIF2α siRNA transfection blocked the effects of salubrinal on 
migration and wound recovery of HUVECs under ER stress (all P < 0.05; Fig. 5d,e). In the tube formation assay 
Figure 4. Salubrinal elevates blood perfusion in ONFH and protects viability of endothelial cells against ER 
stress. (a) Representative histological images of the femoral head by ink perfusion angiography. The vessels 
were indicated by the arrows (40×; Bar = 1 mm). The quantification of the vessel number (b) and vessel area 
percentage (c) in each field of view (200×) was conducted. (d–g) MTT assay for cell viability of HUVECs. The 
histogram showed relative cell viability from three independent experiments. The asterisks (*, ** and ***) 
represent P < 0.05, P < 0.01, and P < 0.001, respectively (S: Salubrinal, and Tm: Tunicamycin).
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(Fig. 5c), tunicamycin decreased cumulative tube lengths (P < 0.001), while salubrinal suppressed tunicamycin’s 
effect (P < 0.05). In accord with the migration, eIF2α siRNA blocked the effect of salubrinal on tube formation of 
HUVECs in the presence of tunicamycin (P < 0.05; Fig. 5f).
To evaluate whether salubrinal affected the p-eIF2α in HUVECs against tunicamycin, we determined the level 
of p-eIF2α in HUVECs at 0, 2, 4, 8, 16, and 32 h after administration of tunicamycin and salubrinal. Tunicamycin 
elevated the level of p-eIF2α at 8 h and peaked it at 32 h. Salubrinal increased the level of p-eIF2α at 4 h, and this 
elevation was kept at 8, 16, and 32 h. Compared to non-salubrinal treatment, salubrinal administration increased 
the level of p-eIF2α in the presence of tunicamycin at 8, 16, and 32 h (all P < 0.05; Fig. 5g,h).
Figure 5. Salubrinal improves migration and angiogenesis of endothelial cells against ER stress by elevating 
p-eIF2α in vitro. (a) Representative images of HUVECs migration by crystal violet staining (200×, 
Bar = 100 μm). (b) Representative images of HUVECs wound-healing (100×, Bar = 200 μm). (c) Representative 
images of HUVECs tube formation (100×, Bar = 200 μm). (d) Numbers of migratory HUVECs. (e) Percentages 
of HUVECs wound recovery. (f) Cumulative tube lengths. The experiments were repeated on three independent 
times. (g) Level of p-eIF2α in HUVECs in the presence of tunicamycin and salubrinal at 6 time points (0, 2, 4, 8, 
16, and 32 h). (h) Ratio of p-eIF2α to total eIF2α. The asterisks (*, **, and ***) represent P < 0.05, P < 0.01, and 
P < 0.001, respectively.
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Salubrinal increases p-eIF2α, ATF4, GRP78 and VEGF, and reduces NFATc1 in ONFH in 
vivo. The images of immunofluorescence showed that p-eIF2α positive cells (green) were mainly located in 
the bone marrow cavity (Fig. 6a). Compared to the sham control group, the ON group increased the expression 
level of p-eIF2α (P < 0.01). The salubrinal-treated group exhibited a further increased level of p-eIF2α (P < 0.01; 
Fig. 6b). Compared to the sham control group, the ON group increased the levels of p-eIF2α, ATF4, and VEGF, 
and decreased the levels of GRP78. The salubrinal-treated group increased the level of p-eIF2α, ATF4, GRP78 and 
VEGF, but it presented a lower level of NFATc1 than that the ON group (all P < 0.05). The level of CHOP was not 
significantly different in three groups (all P > 0.05) (Fig. 6c–i).
Figure 6. Salubrinal increases p-eIF2α, ATF4, GRP78, CHOP and VEGF, and reduces NFATc1 in ONFH 
in vivo. (a) Representative histological immunofluorescence images of femoral head from different groups 
(blue: DAPI, green: p-eIF2α+ cells, 200×, Bar = 100 μm). (b) Numbers of p-eIF2α+ cells were analyzed. (c) 
Representative images of Western blotting in three different groups in vivo. The levels of p-eIF2α (d), ATF4 
(e), GRP78 (f), CHOP (g), VEGF (h), and NFATc1 (i) are shown. The asterisks (* and **) represent P < 0.05, 
and P < 0.01, respectively, and “ns” indicates P > 0.05 (n = 6). (f) Proposed mechanism of salubrinal’s action on 
improving ONFH.
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Correlation exists among p-eIF2α, angiogenesis, vessel remodeling, and bone healing. To 
evaluate the correlation among parameters in salubrinal’s improving of ONFH symptoms, we selected the 
p-eIF2α level for representing salubrinal’s effect, VEGF level for angiogenesis, vessel number for vessel remode-
ling, and osteoblast number and osteoclast surface for bone healing. The result indicated that the level of p-eIF2α 
was positively correlated with the level of VEGF (r = 0.902, P < 0.001) as well as the osteoblast number (r = 0.672, 
P < 0.01). Furthermore, the vessel number was positively correlated with the osteoblast number (r = 0.613, 
P < 0.05) and negatively correlated with the osteoclast surface (r = −0.829, P < 0.001).
Discussion
Interruption of the blood supply to the femoral head is a prime cause of ONFH induction31. In the rat model of 
ONFH, ischemic osteonecrosis was surgically induced and the effect of salubrinal was investigated. Compared to 
the sham control group, the ON group decreased BV/TV, Tb.N, Tb.Th, B.Ar/T.Ar and femoral BMD/BMC, with 
an increase in empty lacunae and Tb.Sp. As reported in the previous ONFH studies12, 16, the results herein are 
consistent with significant bone loss in the femoral head. ONFH also presented the decrease in blood perfusion 
and the level of VEGF16, 32, 33. It presented the fewer vessel number and smaller vessel area than those in the sham 
control group. In orthopaedic diseases such as osteoporosis, osteoarthritis, and osteonecrosis, osteoclastogenesis 
is abnormally activated34–38. The result in this study revealed that osteoclastogenesis was also activated in the 
femoral head of ONFH. The number of TRAP-positive cells was significantly increased in the bone surface of 
ONFH. Furthermore, osteonecrosis activated the differentiation, migration, adhesion, and activity of osteoclasts, 
although osteoblast differentiation in the sham control group was not markedly different from that in the ON 
group.
ONFH primarily results from ischemia/hypoxia to the femoral head. One of the cellular manifestations of 
ischemia/hypoxia is the ER stress. The ER stress is known to lead to three major signaling pathways, such as the 
PERK-ATF4 axis, activating transcription factor 6 (ATF6) axis, and inositol-requiring enzyme-1a/X-box binding 
protein 1 (IRE1a/XBP1) axis1, 26. A unique feature in disease conditions such as ONFH is that the ER stress may 
act as a two-edged sword. While a moderate level may assist the reestablishment of cellular homeostasis, the 
prolonged and unmitigated stress may lead to apoptosis1, 26. In the present model of ONFH, the ischemic femoral 
head was unable to acquire an adequate supply of blood, oxygen, or nutrients20, and the excessive ER stress was 
induced. The result in this study showed that osteonecrosis elevated the level of p-eIF2α and ATF4. The elevated 
level of ATF4, which is induced by the ER stress1, 26, is reported to promote osteoclastogenesis39, 40. In the ONFH 
model, we also observed stimulation in osteoclastogenesis in the ischemic femoral head. Correlation analysis 
indicated that blood perfusion was negatively associated with osteoclastogenesis. Collectively, ischemia in ONFH 
induced osteoclastogenesis and interrupted bone healing by inducing excessive ER stress.
Salubrinal elevates the level of p-eIF2α and activates eIF2α mediated signaling25, and it stimulates bone 
metabolism in orthopaedic diseases27–29. We recently presented several lines of evidence that osteoclastogenesis 
in osteoporosis was associated with the ER stress, and salubrinal suppressed unloading-induced bone loss30. The 
result in this study showed that salubrinal prevented bone loss in ONFH by suppressing osteoclast activity and 
promoting osteoblast development. Salubrinal is reported to suppress osteoclastogenesis by reducing the level of 
NFATc1, and promote osteoblastogenesis by increasing the level of ATF4. The results with NFATc1 and ATF4 in 
this study are consistent with those in the previous studies27, 41.
ATF4 has a dual function in the ER stress pathway. It may serve as a pro-survival factor by promoting tran-
scription of ER chaperones such as GRP78 and reducing the accumulation of misfolded proteins. Alternatively, 
it may lead to apoptosis by inducing CHOP, which is a pro-apoptotic factor26. To evaluate the degree and effect 
of ER stress in the present ONFH model, we determined the levels of GRP78 and CHOP. Although the level of 
CHOP was not detectably different, the level of GRP78 in the ONFH model was significantly decreased. The 
reduction of GRP78 suggests that the ER stress was maintained at the unmitigated level, and the chaperones 
became unavailable under the prolonged ER stress. Salubrinal attenuated prolonged ER stress through the eIF2α 
- ATF4 - GRP78 regulatory axis.
Regarding the effects of salubrinal on angiogenesis, we determined the level of VEGF and its action on 
endothelial cells. The result showed that p-eIF2α increased the expression of ATF41, 26, and ATF4 promoted the 
secretion of VEGF, a stimulator of angiogenesis26, 42–46. Salubrinal protected the proliferation, migration, and 
angiogenesis of HUVECs against the excessive ER stress, which was induced by tunicamycin. Salubrinal also 
increased the p-eIF2α level in HUVECs and increased those of p-eIF2α, ATF4, and VEGF in vivo.
To further evaluate the effect of salubrinal on the ER stress, we employed Calyculin A (CA) as a specific inhib-
itor of PP125. Tunicamycin inhibited the cell viability of MC3T3-E1 cells, while salubrinal and CA suppressed 
tunicamycin’s inhibition. To investigate the in-depth mechanism of salubrinal’s action on the ER stress, RNA 
interference with eIF2α siRNA was conducted. Salubrinal rescued the cell viability of MC3T3-E1 and HUVECs 
under the ER stress. Transfection of eIF2α siRNA blocked the effect of salubrinal on cells viability under ER 
stress. Tunicamycin significantly inhibited the levels of ALP and RUNX2, while salubrinal increased those of 
p-eIF2α, ATF4, ALP, and RUNX2. Treatment with eIF2α siRNA, however, blocked the effects of salubrinal on the 
levels of p-eIF2α, ATF4, ALP, and RUNX2, as well as migration and angiogenesis of HUVECs in the presence of 
tunicamycin. These results indicated that salubrinal protects osteoblasts and endothelial cells against the excessive 
ER stress by modulating the eIF2α signal pathway.
We evaluated toxicity of salubrinal and CA in MC3T3-E1 cells. The result indicated that the non-toxic dose 
of salubrinal and CA were no more than 5 μM and 0.2 nM, respectively. Collectively, salubrinal not only pro-
tected osteogenesis against the ER stress but also had lower toxicity than CA. Furthermore, salubrinal promoted 
osteoblastogenesis, suppressed osteoclastogenesis, and stimulated angiogenesis through suppressing ER stress 
signaling by elevating the level of p-eIF2α in ONFH (Fig. 7). In conclusion, ischemia is an inducer of the ER 
stress in the surgery-induced rat ONFH model, and an excessive ER stress induces osteoclastogenesis and inhibits 
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angiogenesis. Alleviating the ER stress is a potential option to improve symptoms associated with ONFH. The 
present study suggests that the ER stress is an important pathological outcome in the surgery-induced ONFH 
model, in which salubrinal improves the ONFH symptoms by alleviating the ER stress.
Materials and Methods
Preparation of animals and materials. Male Sprague-Dawley rats (~14 weeks of age, Animal Center of 
Academy of Military Medical Sciences, China) were housed on a 12:12 h light-dark cycle under the pathogen-free 
conditions, and were fed with free access to food and water. All experiments were carried out according to the 
National Institutes of Health Guide for Care and Use of Laboratory Animals, and were approved by the Ethics 
Committee of the Tianjin Medical University. Salubrinal was purchased from Tocris Bioscience (Bristol, UK). 
Murine macrophage-colony stimulating factor (M-CSF) and murine receptor activator of nuclear factor kap-
pa-B ligand (RANKL) were purchased from PeproTech (Rocky Hills, NC, USA). Human umbilical vein endothe-
lial cells (HUVECs) and endothelial cell growth medium-2 (EGM2) were purchased from Lonza (Walkersville, 
MD, USA). Lipofectamine 2000 Reagent, Minimum essential medium alpha (MEM-α), Dulbecco’s Modified 
Eagle’s Medium (DMEM), penicillin, streptomycin, fetal bovine serum (FBS) and trypsin were purchased from 
Invitrogen (Carlsbad, CA, USA). Scrambled siRNA and eIF2α siRNA were from GenePharma (Shanghai, china). 
Matrigel was purchased from Life Sciences (Tewksbury, MA, USA). Primary antibodies specific to p-eIF2α, 
ATF4, RUNX2, CHOP and eIF2α were purchased from Cell Signaling (Danvers, MA, USA). The antibody for 
GRP78 was from Thermo (Rockford, AL, USA). The antibodies for ALP, nuclear factor of activated T-cells, 
cytoplasmic 1 (NFATc1), vascular endothelial growth factor (VEGF), and β-actin were purchased from Abcam 
(Cambridge, MA, USA). Other chemicals were purchased from Sigma (St. Louis, MO, USA).
Experimental design. Sixty rats were randomly divided into 4 groups: sham control group (Sham, n = 18), 
osteonecrosis group (ON, n = 18), salubrinal-treated osteonecrosis group (ON + S, n = 18) and salubrinal-treated 
sham control group (Sham + S, n = 6). Ischemic osteonecrosis of the bilateral femoral heads were induced accord-
ing to the procedure previously described12, 47. Briefly, after anesthesia, a longitudinal incision was made on the 
skin over the greater trochanter. The gluteus maximus muscle and the gluteus medius muscle were separated 
from the bone. The joint capsule was transected and the femoral head was dislocated. ONFH was induced by 
transecting the ligamentum teres and tightly placing a ligature (#3-0 Vicryl, Ethicon) around the femoral neck. 
After the femoral head was relocated, muscles and skin were sutured with #3-0 and #4-0 stitches, respectively. For 
sham control and salubrinal-treated sham control groups, rats received the same procedure except for ligating the 
femoral neck and transecting the joint capsule. In addition, analgesia and antibiotic prophylaxis were applied for 
the first three postoperative days. After surgery, a dosage of 0.05 mg/kg salubrinal (resolved in propylene glycol) 
was administered subcutaneously every day for 4 wks to the salubrinal treatment group and salubrinal-treated 
Figure 7. Schematic description of eIF2α signaling regulates ONFH. Ischemia is an inducer of the ER stress in 
the surgery-induced rat ONFH model. Salubrinal promoted osteoblastogenesis, suppressed osteoclastogenesis, 
and stimulated angiogenesis by elevating the level of p-eIF2α through suppressing ER stress signaling in ONFH.
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sham control group28. The sham control and osteonecrosis groups were given the vehicle. All animals were euth-
anised in 4 wks after operation. Bone marrow-derived cells were collected from tibias, and femurs were used for 
imaging and histology.
Micro-computed tomography (μ-CT) and peripheral dual-energy X-ray absorptiometry 
(pDEXA) analysis. Formalin-fixed femurs were examined by μ-CT scanner (VivaCT 40; Scanco Medical 
AG, Bassersdorf, Switzerland) at a voxel size of 10.5 μm. The voxel of interest (VOI) was comprised of 600 CT 
slices. We determined fractional bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), 
and trabecular spacing (Tb.Sp). Furthermore, bone mineral density (BMD) and bone mineral content (BMC) of 
the femur were determined with pDEXA, and changes in BMD and BMC (%) were determined48.
Histological assays. Femoral heads were fixed with 10% neutral buffered formalin for 2 days, and decalci-
fied with 10% ethylenediaminetetraacetic acid (EDTA, pH 7.4) for 40 days. Samples were embedded in paraffin 
and cut into 5-μm thickness coronal slices as previously described47. The ratio of trabecular bone area to tissue 
area (B.Ar/T.Ar), and the percentage of empty lacunae in bone tissue were analyzed using hematoxylin-eosin 
(H&E) staining21, 49. Tartrate resistant acid phosphatase (TRAP) staining were used to detect the percentage of 
osteoclasts49, 50. MacNeal’s staining were used to determine the number of osteoblasts49, 51, 52. For all histological 
assays, three sections were assessed per femoral head and five 100–400× fields were randomly selected per sec-
tion. All graphics were measured and analyzed by Cellsense Standard software (Olympus).
Isolation of bone marrow-derived cells and osteoclast development assay. Bone marrow-derived 
cells were collected as described previously47, 53. After euthanasia, we flushed the bone marrow of tibias with 
DMEM (containing 2% FBS). The cells were separated with Ficoll low-density gradient centrifugation. We seeded 
cells onto 96-well plates at a density of 1 × 105 cells/well, and cultured in MEM-α supplemented with 30 ng/ml 
M-CSF and 20 ng/ml RANKL for 3 days. On day 4, the culture medium was replaced by MEM-α supplemented 
with 30 ng/ml M-CSF and 60 ng/ml RANKL, and cells were grown for additional 3 days. Osteoclasts were iden-
tified using a TRAP staining kit (Sigma-Aldrich). TRAP-positive multinuclear cells (more than 3 nuclei) were 
identified as matured osteoclasts54. In all cell culture experiments, five random fields per well were selected and 
photographed for analysis.
Colony-forming unit-macrophage/mononuclear (CFU-M) and colony-forming unit-granulocyte-macrophage 
(CFU-GM) assays were performed. We seeded bone marrow-derived cells onto 6-well plates at a density of 
2.5 × 104 cells/well. The culture medium was composed of methylcellulose with 30 ng/ml M-CSF and 20 ng/ml 
RANKL. Cells were cultured at 37 °C in a 5% CO2 incubator for 7 days. The colony numbers in CFU-M/CFU-GM 
were converted to the numbers per tibia53, 55.
Migration of pre-osteoclasts was performed with a transwell device as described previously53. To achieve 
pre-osteoclasts, we seeded bone marrow-derived cells (2 × 106 cells/ml in 6-well plates) in MEM-α supplemented 
10% FBS, 30 ng/ml M-CSF and 20 ng/ml RANKL for 4 days. For migration assay, the pre-osteoclasts (1 × 105 cells/
well) were resuspended onto the upper chamber of transwells and allowed to migrate to the bottom cham-
ber through an 8-μm polycarbonate filter coated with vitronectin (Takara Bio Inc., Otsu, Shigma, Japan). The 
medium in the upper chamber was replaced by MEM-α without serum, and MEM-α (consisting of 1% bovine 
serum albumin and 30 ng/ml M-CSF) were loaded onto the lower chamber. After 6 h incubation, the number of 
migrated pre-osteoclasts was counted. For adhesion assay, the pre-osteoclasts (1 × 105 cells/well) were seeded onto 
96-well plates which were coated with vitronectin in MEM-α supplemented with 30 ng/ml M-CSF. The number 
of adherent pre-osteoclasts was counted after 30-min incubation56. For pit formation assay, a UV-sterilized bovine 
cortical bone slices (120 μm thick) were used in bottom of the 24-well plate54. We seeded bone marrow-derived 
cells onto the plate (1 × 105 cells/well), and cultured cells with MEM-α supplemented 10% FBS, 30 ng/ml M-CSF 
and 20 ng/ml RANKL for two days. On the day 3, the concentration of RANKL was increased to 60 ng/ml, and 
the medium was changed every 2 days. On day 10, the percentages of the pit area to total area in each field view 
were calculated. In all above experiments, cells were stained with crystal violet, and five random fields per well 
were selected and photographed for analysis.
Osteoblast differentiation and colony-forming unit-fibroblast (CFU-F) assays. In an osteoblast 
differentiation assay, bone marrow-derived cells were cultured onto 6-well plates (2 × 106 cells/well) with osteo-
genic differentiation medium, and the medium was changed every 2 days. On day 14, cells were stained using an 
alkaline phosphatase (ALP) staining kit (Sigma) and the percentages of ALP-positive cells were determined48.
In a CFU-F assay, bone marrow-derived cells were seeded onto 6-well plates (2 × 106 cells/well) with complete 
MesenCult medium. The medium was changed every 2 days for 14 days. Then, fibroblasts were stained using a 
HEMA-3 quick staining kit (Fisher Scientific, Waltham, MA, USA) and the colonies with more than 50 cells were 
counted57, 58.
Immunofluorescence. Immunofluorescence analysis of the femoral head sections was performed as 
described previously50, 59. Bone sections were permeabilized in 0.3% Triton X-100 for 10 min, and blocked in 
10% goat serum at room temperature for 30 min. Furthermore, the sections were incubated with special primary 
antibodies (p-eIF2α 1:100) overnight at 4 °C. Subsequently, the samples were incubated with secondary antibod-
ies conjugated with fluorescence at room temperature for 1.5 h (avoiding light). The expression of p-eIF2α was 
determined, in which the nuclei were counterstained with DAPI.
Blood perfusion assay. To analyze blood perfusion of the femoral head with ONFH, an ink perfusion assay 
was performed using Chinese ink as previously described33, 47. The heart of rat was exposed by surgery after 
anesthesia. A needle was inserted into the left ventricle for ink infusion, and the right atrium was opened. The 
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circulation were flushed by a heparin-saline solution (25,000 units in 250 ml of 0.9% sodium chloride) until clear 
liquid flowed from the right atrium. With that, 5% gelatin/ink solution (the ratio between Chinese ink and water 
was 1:1) was injected into the circulation until the skin of animals became uniformly black. The femoral heads 
were harvested, and fixed with in 10% neutral buffered formalin for 2 days, and were decalcified in 10% ethyl-
enediaminetetraacetic acid (EDTA, pH 7.4) for 40 days. Samples were embedded in paraffin and cut into 25-μm 
thickness slices. The quantification of vessel numbers was the vessel numbers in each 200× field view, and vessel 
area percentages was the ratio of vessel area to total area in each 200× field view.
Transfection. Transient knockdown of endogenous eIF2α was achieved by siRNA which targeting 
eIF2α. Transfection was performed with Lipofectamine 2000 Reagent (Invitrogen) following the manufac-
turer’s protocol. Briefly, cells were seeded in plates the day before transfection to ensure a suitable cell conflu-
ent on the day of transfection. Scrambled siRNA 5′-ACGUGACACGUUCGGAGATT-3′ or eIF2α siRNA 
5′-AAGCUACUUCAAUAUCU CTT-3′ were used for transfection in antibiotic free Opti-MEM medium 
(Invitrogen). Two days after transfection, the transfected cells were then ready for the following experiments.
Cell viability assay. MTT assay was used to evaluate the cell viability as previously described60. HUVECs 
were seeded in 96-well plates at a density of 1 × 104 cells/well with EGM2. Four hours later, cells were transfected 
with 20 nM eIF2α siRNA or scrambled siRNA, and treated with various treatment factors or vehicle, respec-
tively. After 48 h, the absorbance at 570 nm was detected using a μQuant universal microplate spectrophotometer 
(Bio-tek, Winooski, USA).
Migration and wound-healing assays of HUVECs. Migration of HUVECs was evaluated with 
trans-well equipment as described previously50. HUVECs were transfected with 20 nM eIF2α siRNA or scram-
bled siRNA. 48 h later, cells (2 × 104 cells/well) were suspended in serum-free medium in the upper chambers and 
incubated them with various treatment factors or vehicle. EGM2 (consisting of 20% FBS) were loaded onto the 
lower chamber. The number of cells that migrated to the lower surface in 12 h was counted using crystal violet 
staining. In a wound-healing assay, HUVECs were transfected with 20 nM eIF2α siRNA or scrambled siRNA 
in 6-well plates for 48 h until grown to 100% confluence. Using a 200-μl pipette tip, a scratch was made on a cell 
monolayer. The width of scratch was measured on 0 h and 20 h, respectively, and the percentages of scratch recov-
ery were calculated60.
Tube formation assay of HUVECs. HUVECs were transfected with 20 nM eIF2α siRNA or scram-
bled siRNA for 48 h. We coated 24-well plates with Matrigel and incubated them to polymerize at 37 °C for 
45 min. HUVECs (2 × 105 cells/well) were then seeded on the polymerized Matrigel. Cells were incubated with 
EGM2-containing treatment agents or vehicle for 12 h to stimulate tube formation50. Images of tubes were taken, 
and the cumulative tube lengths were calculated.
Osteogenesis assay in vitro. Cell viability (MTT assay) and the expression levels of osteoblast markers 
were determined under the tunicamycin-induced ER stress. MC3T3-E1 cells were seeded in 96-well plates at a 
density of 1 × 104 cells/well in DMEM with 10% FBS. Four hours later, cells were transfected and were exposed 
to the treatment agents or vehicle. After 48 h, the absorbance at 570 nm was detected in the MTT assay. In 
addition, 48 h after transfection and administration, the expression levels of p-eIF2α, ATF4, ALP, and RUNX2 
inMC3T3-E1 cells were determined by Western blot.
Western blot assay. Bone tissue powders from the femurs or cells were lysed in a RIPA lysis buffer, which 
contained the inhibitors of proteases and phosphatases (Roche Diagnostics GmbH, Mannheim, Germany). The 
levels of p-eIF2α, eIF2α, ALP, RUNX2, ATF4, NFATc1, VEGF, and β-actin were determined by Western blot as 
described previously61. The samples were resolved in sodium dodecyl sulfate-polyacrylamide gel and transferred 
onto the polyvinylidene difluoride membranes. The membranes with primary antibodies were incubated over-
night at 4 °C (p-eIF2α 1:2000, eIF2α 1:4000, ALP 1:2000, RUNX2 1:1000, ATF4 1:1000, NFATc1 1:2000, VEGF 
1:2000, GRP78 1:20000, CHOP 1:1000 and β-actin 1:10000). Soon afterwards, the membranes were washed and 
incubated with horseradish peroxidase-conjugated secondary antibody (1:20000). Enhanced chemiluminescence 
was used to assess protein expression. Image acquisition and analysis software (Bio-rad) were used to quantify 
band intensities.
Statistical analysis. Data were expressed as mean ± standard deviation (SD). Data were analyzed with 
independent-sample t test (for two groups) or one-way ANOVA (for more than two groups). Correlation analysis 
among parameters was performed by Pearson correlation coefficient test. Statistical significance was assumed at 
P < 0.05. The asterisks (*, **, and ***) represent P < 0.05, P < 0.01, and P < 0.001, respectively.
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